What is Axonal sensorimotor peripheral polyneuropathy

My doctor has told me I have this,is this something that is treatable?What is involved in the treatment?

The peripheral nervous system can be involved in a wide range of medical disorders with various pathophysiologies (Table 1).1 It may be affected by numerous toxins, both drugs (Table 2) and industrial agents (Table 3), and by a variety of chronic infections, including human immunodeficiency virus (HIV). Furthermore, a number of apparently immune-mediated disorders result in peripheral neuropathies, including Guillain-Barr茅 syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and multifocal motor neuropathy with conduction block syndrome (MMNCB).2 Finally, a host of hereditary polyneuropathies may cause a wide range of peripheral neuropathy syndromes (Table 4).

This diverse array of possible etiologies can make the diagnosis of peripheral neuropathies quite challenging. Nevertheless, diagnosis can be facilitated with a systematic approach that classifies the peripheral neuropathy on the basis of clinical features, taking into account the type of peripheral nerve fiber that may be involved ( ie, sensory, motor, or autonomic), the distribution or pattern of peripheral nerve-fiber involvement (ie, generalized and symmetric versus asymmetric and multifocal), and lastly, the mode of evolution (ie, acute, subacute, or chronic).

THERAPY

Specific therapies for polyneuropathy are based upon the precise etiologic diagnosis. In those disorders attributed to underlying medical conditions, management is focused on the medical disorder. For example, optimizing glycemic control in diabetic polyneuropathy will often stabilize or improve the polyneuropathy. In patients with idiopathic immune-mediated polyneuropathies, including GBS, CIDP, and MMNCB (multifocal motor neuropathy with conduction block), specific immune-modulating therapies are often recommended.2,11 For GBS, intravenous gamma globulin (IVIg), typically administered at a dosage of 400 mg/kg daily for 5 consecutive days, is initiated early in the patient's course. Alternatively, plasmapheresis may also be instituted as initial therapy. Treatment of CIDP may begin with corticosteroid therapy; however, chronic IVIg and/or plasmapheresis are usually very effective and obviate the need for long-term steroid therapy. Toxic polyneuropathies are managed by discontinuing the offending drug or removing the industrial toxin from the patient's environment. Management of hereditary polyneuropathies includes education of the affected family members regarding the nature and genetic features of the disorder and judicious screening of family members at risk.